A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis

Study Overview
=================
Brief Summary
-----------------
This is a multicenter, open-label study to evaluate the safety and tolerability and explore the efficacy of FCR001 cell therapy in adults with rapidly progressive Diffuse Cutaneous Systemic Sclerosis (dcSSc) at risk for organ failure.

Detailed Description
-----------------
The purpose of this multicenter, single-arm study is to evaluate the safety and tolerability and explore the efficacy of FCR001 cell therapy in adults with rapidly progressive dcSSc at risk for organ failure. It consists of 2 years of treatment and 3 years of follow-up, with the primary analysis performed at 24 months. FCR001 is a cell therapy product that is administered by intravenous (IV) infusion, following nonmyeloablative (NMA) conditioning. It consists of mobilized peripheral blood cells, facilitating cells, and αβ T cells. This therapy is designed to induce donor-specific tolerance by establishing sustained chimerism and to protect against graft versus host disease (GvHD), the major impediment for advancing allogeneic hematopoietic stem cell therapy (HSCT) as a potential therapy in patients.

Official Title
-----------------
A Single-arm, Multi-center, Open-label Proof of Concept Safety and Efficacy Study of FCR001 Cell-based Therapy in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis at Risk for Organ Failure

Conditions
-----------------
Diffuse Cutaneous Systemic Sclerosis

Intervention / Treatment
-----------------
* Biological: FCR001


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria (Recipients): Age ≥ 18 and < 70 years Diagnosis of diffuse cutaneous systemic sclerosis Disease duration < 5 years from first non-Raynaud's phenomenon symptom Received at least one immunosuppressant in the past to treat the systemic sclerosis (SSc) or currently on an immunosuppressive therapy Modified Rodnan Skin Score > 15 and < 40 Documented evidence of pulmonary or renal involvement by having at least one of the following: a) Pulmonary, both required: i. FVC > 45% and < 80% predicted or hemoglobin-adjusted DLco > 45% and < 80% predicted AND ii. Interstitial lung disease evidenced by chest high-resolution computed tomography b) Renal: history of renal crisis that is not active at time of screening. Stable serum creatinine (< 20% increase) must be documented for a minimum of 3 months post-renal crisis at the time of the screening visit. Key Inclusion Criteria (Donors): Age ≥ 18 and < 60 years Key Exclusion Criteria (Donor and Recipient): Use of investigational drugs within 30 days (or within 5 drug half-lives) of signing informed consent Pregnant or nursing (lactating) woman Human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) positive. Those with history of HCV infection which was successfully treated and cured may participate History of malignancy (other than localized squamous or basal cell carcinoma of the skin or in-situ cervical cancer without recurrence) or premalignant syndrome within the past 5 years Known bone marrow aplasia Key Exclusion Criteria (Recipient): Rheumatic disease, other than systemic sclerosis FVC < 45% of predicted or hemoglobin-adjusted DLco < 45% of predicted Pulmonary arterial hypertension (PAH) An LVEF < 50% by echocardiogram or clinical evidence of significant CHF (New York Heart Association Class III or IV) or symptomatic cardiac disease or uncontrolled clinically significant arrhythmias Estimated GFR < 40 mL/min Previous treatment with cyclophosphamide, as defined by combination of prior oral and intravenous cyclophosphamide > 9 months, independent of dose Corticosteroid therapy at prednisone equivalent doses of greater than 10 mg/day, or more than two pulses for concurrent illnesses within prior 12 months Uncontrolled hypertension Active gastric antral vascular ectasia, also known as watermelon stomach Use of scleroderma specific therapies beyond protocol specified washout period, except for PDE-5 inhibitors for Raynaud's phenomenon and digital ulcers Previous history of bone marrow transplant, total lymphoid irradiation, solid organ transplant, autologous or allogeneic hematopoietic progenitor or mesenchymal stem cell transplant Presence of donor-specific antibodies Body mass index < 18 or > 35 kg/m^2 Key Exclusion Criteria (Donor): Biologically unrelated female donor to male recipient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: FCR001<br>FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood cells and delivered as a single infusion with a nonmyeloablative conditioning regimen. | Biological: FCR001<br>* Enriched hematopoietic stem cell infusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of recipient adverse events (AEs) |  | From day before infusion to 60 months | 
| Incidence of recipient serious adverse events (SAEs) |  | From day before infusion to 60 months | 
| Occurrence of Graft versus Host Disease (GvHD) |  | From infusion to 60 months | 
| Time to neutrophil recovery |  | From infusion to 28 days | 
| Time to platelet recovery |  | From infusion to 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent donor whole blood chimerism |  | From infusion to 60 months | 
| Percentage of donor T-cell chimerism |  | From infusion to 60 months | 
| Incidence of donor AEs |  | From donation to 12 months | 
| Incidence of donor SAEs |  | From donation to 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stem cell therapy, Scleroderma, Severe scleroderma, Allogeneic, Transplant